Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration
Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA-511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in Phase 1b study
WATERTOWN, Mass., November 16, 2026 – Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
“We’ve been in a period of strong execution across our pipeline, including the submission of our IND for NMRA-215 in obesity and the NMRA-511 data we reported today, which suggest we can build on the unsurpassed efficacy seen in our Phase 1b study in AD agitation,” said Joshua Pinto, Ph.D., president and chief executive officer, Neumora. “We remain disciplined in allocating capital to the programs with the greatest potential to create value for patients and shareholders, and we are actively evaluating options to fund our lead programs through their next value inflection points.”
KEY PIPELINE HIGHLIGHTS
NMRA-215 (NLRP3 Inhibitor):
Neumora is developing NMRA-215, a potentially best-in-class, highly brain-penetrant oral NLRP3 inhibitor, for the treatment of obesity and cardiometabolic disease and has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.
Additionally, Neumora today announced the presentation of preclinical results from NMRA-215 at ObesityWeek 2026. The presentation highlighted preclinical findings from diet-induced obesity (DIO) mouse studies of NMRA-215, in which NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with incretin-like induction and up to 26% in combination with semaglutide.
NMRA-511 (Vasopressin 1a Receptor Antagonist):
Neumora today announced results from the multiple ascending dose (MAD) expansion cohort evaluating a 30 mg BID dose of NMRA-511 in healthy elderly participants. The 30 mg BID dose demonstrated a favorable safety and tolerability profile with no serious adverse events, and dose-proportional increases in exposure compared to the 20 mg BID dose evaluated in the Phase 1b study. The Company believes the 30 mg BID dose may build on the strong efficacy established with the 20 mg BID dose in the Phase 1b study, and the program is Phase 2 enabled.
Additionally, Neumora recently presented data from the NMRA-511 Phase 1b study at the Neuroscience Education Institute (NEI) Fall Congress.
NMRA-898 (M4 Positive Allosteric Modulator):
The Phase 1 MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia is ongoing.
THIRD QUARTER 2026 FINANCIAL RESULTS
